Group 1 - The core viewpoint of the article highlights the strategic collaboration between Innovent Biologics and Eli Lilly to jointly develop novel biologics focused on oncology and immunology globally [1] - The partnership is viewed as a positive surprise and marks a significant milestone in Innovent Biologics' journey towards becoming a global biopharmaceutical company, showcasing the strength of its R&D platform [1] - Innovent Biologics' management reiterated its long-term vision, primarily supported by a dual-engine growth strategy in the areas of generic biologics and oncology drugs [1] Group 2 - The report emphasizes the impressive execution capabilities of Innovent Biologics in its commercial and R&D product lines, as well as its strong business development abilities [1] - The firm maintains that Innovent Biologics is one of its top picks among Chinese biotech companies, reiterating an "overweight" rating with a target price of HKD 111 [1]
大行评级丨小摩：重申信达生物为生物科技行业首选标的之一，与礼来合作属正面惊喜